Study #2018-0538
Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with atezolizumab in patients with recurrent and/or refractory solid tumors (ACTengine® IM
MD Anderson Study Status
Enrolling
Treatment Agent
IMA203 Product, nivolumab (Opdivo®), IMA203 product- flat dose, IMA203CD8 Product
Description
The study purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Study phase:
Phase I
Physician name:
Dejka Araujo
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.